U.S. Markets closed

Progenics Pharmaceuticals, Inc. (PGNX)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
7.51-0.09 (-1.18%)
At close: 4:00PM EDT
People also watch
NBIXARRYRIGLSGYPPTIE

Progenics Pharmaceuticals, Inc.

One World Trade Center
47th Floor
New York, NY 10007
United States
646-975-2500
http://www.progenics.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees58

Key Executives

NameTitlePayExercisedAge
Mr. Mark R. Baker J.D.Chief Exec. Officer and Director962.64kN/A62
Mr. Patrick FabbioChief Financial Officer and Sr. VP509.07kN/A49
Dr. Vivien Wong Ph.D.Exec. VP of Devel.555.13kN/A60
Mr. Jeffrey D. SummerSr. VP of Strategy & Performance305.22kN/A57
Mr. Bryce V. TenbargeVP of Commercial171.84kN/A44
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Progenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. The company’s primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant and/or recurrent pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule that has completed Phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer. Its clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small radiopharmaceutical molecule for the treatment of metastatic castration-resistant prostate cancer; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in pre-clinical stage for treatment of metastatic prostate cancer; and EXINI bone BSI range of prostate cancer bone scan indexing products. The company also offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness adult patients receiving palliative care when laxative therapy has not been sufficient, as well as for treatment of OIC in patients with non-cancer pain; and Relistor-oral tablets for the treatment of OIC. The company has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and with Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA, as well as has collaboration agreement with Seattle Genetics, Inc. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York, New York.

Corporate Governance

Progenics Pharmaceuticals, Inc.’s ISS Governance QualityScore as of June 2, 2017 is 1. The pillar scores are Audit: 2; Board: 2; Shareholder Rights: 1; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.